{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:50:05Z","timestamp":1792245005442,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:00:00Z","timestamp":1676419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03317-7","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T02:17:14Z","timestamp":1676600234000},"page":"303-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Modern approach to resistant acromegaly"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-3398","authenticated-orcid":false,"given":"Andrea","family":"Giustina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melin M.","family":"Uygur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Frara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,15]]},"reference":[{"issue":"6","key":"3317_CR1","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"S. Melmed, U.B. Kaiser, M.B. Lopes et al. Clinical biology of the pituitary adenoma. Endocr. Rev. 43(6), 1003\u20131037 (2022). https:\/\/doi.org\/10.1210\/endrev\/bnac010","journal-title":"Endocr. Rev."},{"issue":"4","key":"3317_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.tem.2020.01.011","volume":"31","author":"A Giustina","year":"2020","unstructured":"A. Giustina, Acromegaly and vertebral fractures: facts and questions. Trends Endocrinol. Metab. 31(4), 274\u2013275 (2020). https:\/\/doi.org\/10.1016\/j.tem.2020.01.011","journal-title":"Trends Endocrinol. Metab."},{"issue":"15","key":"3317_CR3","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/s0002-9149(99)80721-8","volume":"75","author":"A Giustina","year":"1995","unstructured":"A. Giustina, E. Boni, G. Romanelli, V. Grassi, G. Giustina, Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am. J. Cardiol. 75(15), 1042\u20131047 (1995). https:\/\/doi.org\/10.1016\/s0002-9149(99)80721-8","journal-title":"Am. J. Cardiol."},{"issue":"1","key":"3317_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12020-011-9486-x","volume":"40","author":"G Mazziotti","year":"2011","unstructured":"G. Mazziotti, M. Gola, A. Bianchi et al. Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40(1), 102\u2013108 (2011). https:\/\/doi.org\/10.1007\/s12020-011-9486-x","journal-title":"Endocrine"},{"issue":"4","key":"3317_CR5","doi-asserted-by":"publisher","first-page":"dgz096","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"A. Giustina, A. Barkan, A. Beckers et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105(4), dgz096 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Aug 8","key":"3317_CR6","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1701\/2332.25074","volume":"107","author":"A Giustina","year":"2016","unstructured":"A. Giustina, Acromegalia: ridurre il ritardo della diagnosi [Acromegaly: reducing diagnostic delay]. Recent. Prog. Med 107(Aug 8), 450\u2013451 (2016). https:\/\/doi.org\/10.1701\/2332.25074. ItalianPMID: 27571562","journal-title":"Recent. Prog. Med"},{"issue":"6","key":"3317_CR7","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11102-022-01266-4","volume":"25","author":"S Chiloiro","year":"2022","unstructured":"S. Chiloiro, A. Giampietro, I. Gagliardi et al. Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary 25(6), 831\u2013841 (2022). https:\/\/doi.org\/10.1007\/s11102-022-01266-4","journal-title":"Pituitary"},{"issue":"4","key":"3317_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"A. Giustina, G. Barkhoudarian, A. Beckers et al. Multidisciplinary management of acromegaly: A consensus. Rev. Endocr. Metab. Disord. 21(4), 667\u2013678 (2020). https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"3","key":"3317_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ecl.2020.05.010","volume":"49","author":"S Frara","year":"2020","unstructured":"S. Frara, G. Rodriguez-Carnero, A.M. Formenti, M.A. Martinez-Olmos, A. Giustina, F.F. Casanueva, Pituitary tumors centers of excellence. Endocrinol. Metab. Clin. North Am. 49(3), 553\u2013564 (2020). https:\/\/doi.org\/10.1016\/j.ecl.2020.05.010","journal-title":"Endocrinol. Metab. Clin. North Am."},{"issue":"5","key":"3317_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"F.F. Casanueva, A.L. Barkan, M. Buchfelder et al. Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a pituitary society statement. Pituitary 20(5), 489\u2013498 (2017). https:\/\/doi.org\/10.1007\/s11102-017-0838-2","journal-title":"Pituitary"},{"issue":"4","key":"3317_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11154-020-09564-7","volume":"21","author":"P Mortini","year":"2020","unstructured":"P. Mortini, G. Nocera, F. Roncelli, M. Losa, A.M. Formenti, A. Giustina, The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective. Rev. Endocr. Metab. Disord. 21(4), 527\u2013536 (2020). https:\/\/doi.org\/10.1007\/s11154-020-09564-7","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"1","key":"3317_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.0300-0664.2001.01438.x","volume":"56","author":"G Amato","year":"2002","unstructured":"G. Amato, G. Mazziotti, M. Rotondi et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin. Endocrinol. (Oxf.) 56(1), 65\u201371 (2002). https:\/\/doi.org\/10.1046\/j.0300-0664.2001.01438.x","journal-title":"Clin. Endocrinol. (Oxf.)"},{"issue":"5","key":"3317_CR13","doi-asserted-by":"publisher","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","volume":"7","author":"A Giustina","year":"2012","unstructured":"A. Giustina, G. Mazziotti, V. Torri, M. Spinello, I. Floriani, S. Melmed, Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 7(5), e36411 (2012). https:\/\/doi.org\/10.1371\/journal.pone.0036411","journal-title":"PLoS One"},{"issue":"1","key":"3317_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","volume":"13","author":"G Mazziotti","year":"2010","unstructured":"G. Mazziotti, A. Giustina, Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13(1), 60\u201367 (2010). https:\/\/doi.org\/10.1007\/s11102-009-0169-z","journal-title":"Pituitary"},{"issue":"1","key":"3317_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/BF03349183","volume":"29","author":"M Gola","year":"2006","unstructured":"M. Gola, S. Bonadonna, G. Mazziotti, G. Amato, A. Giustina, Resistance to somatostatin analogs in acromegaly: an evolving concept. J. Endocrinol. Invest 29(1), 86\u201393 (2006). https:\/\/doi.org\/10.1007\/BF03349183","journal-title":"J. Endocrinol. Invest"},{"issue":"7","key":"3317_CR16","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1210\/jc.2009-2670","volume":"95","author":"A Giustina","year":"2010","unstructured":"A. Giustina, P. Chanson, M.D. Bronstein et al. A consensus on criteria for cure of acromegaly. J. Clin. Endocrinol. Metab. 95(7), 3141\u20133148 (2010). https:\/\/doi.org\/10.1210\/jc.2009-2670","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"3317_CR17","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1210\/clinem\/dgab536","volume":"106","author":"A Giustina","year":"2021","unstructured":"A. Giustina, M.D. Bronstein, P. Chanson et al. International multicenter validation study of the SAGIT\u00ae instrument in acromegaly. J. Clin. Endocrinol. Metab. 106(12), 3555\u20133568 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab536","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"3317_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s11102-019-00977-5","volume":"22","author":"A Giustina","year":"2019","unstructured":"A. Giustina, M.D. Bronstein, P. Chanson et al. Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT\u00ae validation study. Pituitary 22(5), 476\u2013487 (2019). https:\/\/doi.org\/10.1007\/s11102-019-00977-5","journal-title":"Pituitary"},{"key":"3317_CR19","doi-asserted-by":"publisher","unstructured":"C.G.B. Herkenhoff, E.B. Trarbach, R.L. Batista et al. Survivin: a potential marker of resistance to somatostatin receptor ligands [published online ahead of print, 2022 Oct 24]. J. Clin. Endocrinol. Metab. dgac610 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgac610","DOI":"10.1210\/clinem\/dgac610"},{"issue":"1","key":"3317_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/jcm12010025","volume":"12","author":"AM Berton","year":"2022","unstructured":"A.M. Berton, N. Prencipe, L. Bertero et al. Resistance to somatostatin analogs in Italian Acromegaly patients: the MISS study. J. Clin. Med. 12(1), 25 (2022). https:\/\/doi.org\/10.3390\/jcm12010025. Published 2022 Dec 20","journal-title":"J. Clin. Med."},{"key":"3317_CR21","doi-asserted-by":"publisher","first-page":"8660470","DOI":"10.1155\/2022\/8660470","volume":"2022","author":"G Kontogeorgos","year":"2022","unstructured":"G. Kontogeorgos, V. Markussis, E. Thodou et al. Association of pathology markers with somatostatin analogue responsiveness in acromegaly. Int J. Endocrinol. 2022, 8660470 (2022). https:\/\/doi.org\/10.1155\/2022\/8660470","journal-title":"Int J. Endocrinol."},{"issue":"7","key":"3317_CR22","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1210\/jc.2008-0126","volume":"93","author":"A Fusco","year":"2008","unstructured":"A. Fusco, M.C. Zatelli, A. Bianchi et al. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 93(7), 2746\u20132750 (2008). https:\/\/doi.org\/10.1210\/jc.2008-0126","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"3317_CR23","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","volume":"107","author":"MD Ilie","year":"2022","unstructured":"M.D. Ilie, A. Tabarin, A. Vasiljevic et al. Predictive factors of somatostatin receptor ligand response in acromegaly-A prospective study. J. Clin. Endocrinol. Metab. 107(11), 2982\u20132991 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgac512","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"3317_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-09-0372","volume":"161","author":"A Giustina","year":"2009","unstructured":"A. Giustina, S. Bonadonna, G. Bugari et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur. J. Endocrinol. 161(2), 331\u2013338 (2009). https:\/\/doi.org\/10.1530\/EJE-09-0372","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"3317_CR25","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2017-00142","volume":"102","author":"A Giustina","year":"2017","unstructured":"A. Giustina, G. Mazziotti, S. Cannav\u00f2 et al. High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study. J. Clin. Endocrinol. Metab. 102(7), 2454\u20132464 (2017). https:\/\/doi.org\/10.1210\/jc.2017-00142","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5-6","key":"3317_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1006\/phrs.1996.0095","volume":"34","author":"A Giustina","year":"1996","unstructured":"A. Giustina, G. Zaltieri, F. Negrini, W.B. Wehrenberg, The pharmacological aspects of the treatment of acromegaly. Pharm. Res 34(5-6), 247\u2013268 (1996). https:\/\/doi.org\/10.1006\/phrs.1996.0095","journal-title":"Pharm. Res"},{"issue":"10","key":"3317_CR27","doi-asserted-by":"publisher","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","volume":"105","author":"SL Samson","year":"2020","unstructured":"S.L. Samson, L.B. Nachtigall, M. Fleseriu et al. Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide. J. Clin. Endocrinol. Metab. 105(10), e3785\u2013e3797 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgaa526","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"3317_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1530\/EJE-22-0220","volume":"187","author":"SL Samson","year":"2022","unstructured":"S.L. Samson, L.B. Nachtigall, M. Fleseriu et al. Durable biochemical response and safety with oral octreotide capsules in acromegaly. Eur. J. Endocrinol. 187(6), 733\u2013741 (2022). https:\/\/doi.org\/10.1530\/EJE-22-0220. Published 2022 Oct 26","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"3317_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"A. Colao, L.F.S. Grasso, A. Giustina et al. Acromegaly [published correction appears in Nat Rev Dis Primers. 2019 Oct 21;5(1):72]. Nat. Rev. Dis. Prim. 5(1), 20 (2019). https:\/\/doi.org\/10.1038\/s41572-019-0071-6. Published 2019 Mar 21","journal-title":"Nat. Rev. Dis. Prim."},{"key":"3317_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/bs.pmbts.2015.10.015","volume":"138","author":"S Frara","year":"2016","unstructured":"S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, The modern criteria for medical management of acromegaly. Prog. Mol. Biol. Transl. Sci. 138, 63\u201383 (2016). https:\/\/doi.org\/10.1016\/bs.pmbts.2015.10.015","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"7","key":"3317_CR31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol. Metab. 27(7), 470\u2013483 (2016). https:\/\/doi.org\/10.1016\/j.tem.2016.04.014","journal-title":"Trends Endocrinol. Metab."},{"issue":"9","key":"3317_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"S. Melmed, M.D. Bronstein, P. Chanson et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552\u2013561 (2018). https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"3317_CR33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","volume":"40","author":"A Giustina","year":"2017","unstructured":"A. Giustina, G. Arnaldi, F. Bogazzi et al. Pegvisomant in acromegaly: an update [published correction appears in J Endocrinol Invest. 2017 Dec 28;:]. J. Endocrinol. Invest 40(6), 577\u2013589 (2017). https:\/\/doi.org\/10.1007\/s40618-017-0614-1","journal-title":"J. Endocrinol. Invest"},{"issue":"1","key":"3317_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12020-014-0462-0","volume":"48","author":"A Giustina","year":"2015","unstructured":"A. Giustina, Optimal use of pegvisomant in acromegaly: are we getting there. Endocrine 48(1), 3\u20138 (2015). https:\/\/doi.org\/10.1007\/s12020-014-0462-0","journal-title":"Endocrine"},{"issue":"10","key":"3317_CR35","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40618-014-0146-x","volume":"37","author":"A Giustina","year":"2014","unstructured":"A. Giustina, M.R. Ambrosio, P. Beck Peccoz et al. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J. Endocrinol. Invest 37(10), 1017\u20131030 (2014). https:\/\/doi.org\/10.1007\/s40618-014-0146-x","journal-title":"J. Endocrinol. Invest"},{"issue":"2","key":"3317_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12020-015-0810-8","volume":"52","author":"SE Franck","year":"2016","unstructured":"S.E. Franck, A. Muhammad, A.J. van der Lely, S.J. Neggers, Combined treatment of somatostatin analogues with pegvisomant in acromegaly. Endocrine 52(2), 206\u2013213 (2016). https:\/\/doi.org\/10.1007\/s12020-015-0810-8","journal-title":"Endocrine"},{"issue":"10","key":"3317_CR37","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1210\/jc.2008-0669","volume":"93","author":"SJ Neggers","year":"2008","unstructured":"S.J. Neggers, M.O. van Aken, W.W. de Herder et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab. 93(10), 3853\u20133859 (2008). https:\/\/doi.org\/10.1210\/jc.2008-0669","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"3317_CR38","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1210\/jc.2008-2332","volume":"94","author":"G Mazziotti","year":"2009","unstructured":"G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, A. Giustina, Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94(5), 1500\u20131508 (2009). https:\/\/doi.org\/10.1210\/jc.2008-2332","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"3317_CR39","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","volume":"73","author":"S Chiloiro","year":"2021","unstructured":"S. Chiloiro, A. Giampietro, F. Visconti et al. Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine 73(3), 658\u2013666 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02711-3","journal-title":"Endocrine"},{"issue":"11","key":"3317_CR40","doi-asserted-by":"publisher","first-page":"5478","DOI":"10.1210\/jc.2019-00825","volume":"104","author":"S Chiloiro","year":"2019","unstructured":"S. Chiloiro, C. Bima, T. Tartaglione et al. Pasireotide and pegvisomant combination treatment in acromegaly resistant to second-line therapies: a longitudinal study. J. Clin. Endocrinol. Metab. 104(11), 5478\u20135482 (2019). https:\/\/doi.org\/10.1210\/jc.2019-00825","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"3317_CR41","doi-asserted-by":"publisher","first-page":"101684","DOI":"10.1016\/j.beem.2022.101684","volume":"36","author":"S Chiloiro","year":"2022","unstructured":"S. Chiloiro, A. Bianchi, A. Giampietro, A. Pontecorvi, G. Raverot, L. Marinis, Second line treatment of acromegaly: Pasireotide or Pegvisomant? Best. Pr. Res Clin. Endocrinol. Metab. 36(6), 101684 (2022). https:\/\/doi.org\/10.1016\/j.beem.2022.101684","journal-title":"Best. Pr. Res Clin. Endocrinol. Metab."},{"issue":"2","key":"3317_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-20-0767","volume":"184","author":"S Chiloiro","year":"2021","unstructured":"S. Chiloiro, A. Giampietro, F. Mirra et al. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur. J. Endocrinol. 184(2), 217\u2013229 (2021). https:\/\/doi.org\/10.1530\/EJE-20-0767","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"3317_CR43","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1210\/jc.2008-1337","volume":"94","author":"A Bianchi","year":"2009","unstructured":"A. Bianchi, A. Giustina, V. Cimino et al. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J. Clin. Endocrinol. Metab. 94(6), 2015\u20132022 (2009). https:\/\/doi.org\/10.1210\/jc.2008-1337","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"3317_CR44","doi-asserted-by":"publisher","first-page":"e2843","DOI":"10.1210\/clinem\/dgac183","volume":"107","author":"S Frara","year":"2022","unstructured":"S. Frara, M. Melin Uygur, L. di Filippo et al. High prevalence of vertebral fractures associated with preoperative GH levels in patients with recent diagnosis of acromegaly. J. Clin. Endocrinol. Metab. 107(7), e2843\u2013e2850 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgac183","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"3317_CR45","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1210\/jc.2013-1460","volume":"98","author":"G Mazziotti","year":"2013","unstructured":"G. Mazziotti, A. Bianchi, T. Porcelli et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J. Clin. Endocrinol. Metab. 98(8), 3402\u20133410 (2013). https:\/\/doi.org\/10.1210\/jc.2013-1460","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"3317_CR46","doi-asserted-by":"publisher","first-page":"dgz054","DOI":"10.1210\/clinem\/dgz054","volume":"105","author":"S Chiloiro","year":"2020","unstructured":"S. Chiloiro, A. Giampietro, S. Frara et al. Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs. J. Clin. Endocrinol. Metab. 105(3), dgz054 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgz054","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03317-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03317-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03317-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T12:29:09Z","timestamp":1682598549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03317-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,15]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["3317"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03317-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,15]]},"assertion":[{"value":"2 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A.G. is a consultant for Abiogen, Ipsen, Pfizer, Recordati and Takeda, and received research grants from Institution from Pfizer and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}